Targeting nuclear acid-mediated immunity in cancer immune checkpoint inhibitor therapies

Miaojun Chen, Shiman Hu, Yiling Li, Ting Ting Jiang, Hongchuan Jin and Lifeng Feng

Cancer immunotherapy especially immune checkpoint inhibition has achieved unprecedented successes in cancer treatment. However, there are many patients who failed to benefit from these therapies, highlighting the need for new combinations to increase the clinical efficacy of immune checkpoint inhibitors. In this review, we summarized the latest discoveries on the combination of nucleic acid-sensing immunity and immune checkpoint inhibitors in cancer immunotherapy. Given the critical role of nuclear acid-mediated immunity in maintaining the activation of T cell function, it seems that harnessing the nuclear acid-mediated immunity opens up new strategies to enhance the effect of immune checkpoint inhibitors for tumor control.

INTRODUCTION
Cancer immunotherapy, exploiting to activate the immune system to fight malignancies, has become a major strategy for a long time. Early in 1891, William Cooley attempted to treat sarcoma via intratumoral injections of Streptococcus pyogenes and Serratia marcescens to activate immunity. Currently, the most commonly used strategy is the inhibition of immune checkpoints, particularly targeting the programmed cell death receptor-1 (PD-1), and its ligand, programmed cell death ligand-1 (PD-L1) and cytotoxic T lymphocyte-associated protein 4 (CTLA4). Nivolumab, pembrolizumab and camrelizumab are approved PD-1 blocking agents, while atezolizumab, avelumab, and durvalumab are approved PD-L1 blocking antibodies. Widely, these agents have been applied to the treatment of a variety of advanced tumors, including metastatic melanoma, non-small-cell lung cancer, gastric carcinoma, hepatocellular carcinomas, renal cell carcinoma, etc.

Despite the dramatic therapeutic responses, these agents provide durable clinical responses only in nearly 20% of cancer patients as monotherapy. And there are many complicated mechanisms of primary or acquired resistance to immune checkpoint blockade. As the central of immune checkpoint inhibitors (ICIs) is to reactivate effector T cells, the resistance mainly resulted from inadequate infiltration or impaired function of T cells in the tumor microenvironment.

As the first line of defense, innate immune cells are critical in the onset and maintenance of T cell responses, including T-cell-centered tumor immunity. Briefly, antigen-presenting cells (APCs) uptake and present tumor antigens via major histocompatibility complex I (MHC-I), and thereby induce tumor-specific CD8+ T cell expansion. In addition, some APCs such as cDC1s (a subset of conventional dendritic cells) can also produce chemokines including CXCL9 and CXCL10 to recruit T cells to tumor microenvironment. Nature killer cells (NK cells), another important class of innate immune cells, can kill targeted tumor cells, secrete anti-tumor cytokines, and also contribute to the infiltration of cDC1s into tumors.

The critical signals to induce immune responses include pathogen-derived toxins like LPS and ectopic genetic materials such as exogenous or cytosolic nuclear acids. Meanwhile, the so-called pattern recognition receptors (PRRs) are proteins which engaged in detecting the pathogen-associated molecular patterns and transduction the signalings of infectious agents elimination. More importantly, the organism activates the innate immune system relying on the PRRs mediated signaling. Nucleic acid sensors, which can detect extracellular or intracellular DNA or RNA as damage-associated molecular pattern signals, are the essential part of the PRRs. Upon activation, Nucleic acid sensors can induce type I interferons (IFNs). Type I IFNs are known for their critical roles in antiviral immune responses. The secreted Type I IFNs will act on producing and neighboring cells via IFNα/β receptor 1 (IFNAR1, particularly high affinity for IFNB) or IFNAR1-IFNAR2 heterodimer. Type I IFNs support cytotoxic T lymphocytes (CTLs) via several mechanisms. Firstly, they promote stimulating the maturation of DCs to improve cross-priming with T cells; secondly, they increase the expression of perforin 1 and granzyme B to boost functions of effect T cells; thirdly, they can inactivate the suppressive function of regulatory T (Treg) cells; finally, Type I IFNs can prevent NK cells to eliminate antigen-activated CD8+ CTLs, and induce macrophages to release pro-inflammatory cytokines (such as IL-1β, and IL-18).

As combinatorial strategies are required and enhanced, the combination of releasing the multiple brakes on T cells via ICIs and unleashing the innate immunity to activate T cell functions is a promising strategy to control tumor development. Here, we review the roles of nucleic acid sensors in innate or adaptive immunity, and the mechanisms which can influence the sensitiveness and effectiveness of the ICIs to anti-tumor. Our discussion focuses on the latest discoveries on the synergy of nucleic acid...
sensors-mediated innate immunity and ICIs as the promising signal in cancer immunotherapy.

**NUCLEIC ACID SENSORS**

Retinoic acid-inducible gene-I (RIG-I) like receptors (RLRs), including RIG-I, melanoma differentiation-associated protein 5 (MDA5), and laboratory of genetics and physiology 2 (LGP2), are expressed in the cytosol of most immune and non-immune cells, including cancer cells. RLRs are common in sharing the DExD/H-box helicase domain and C-terminal domain (CTD), and RIG-I and MDA5 contain two N-terminal tandem caspase activation and recruitment domains (CARD), whereas LGP2 recognized long dsRNA structures. LGP2 can bind RNA ligands of RIG-I, interfering with IKK recruitment to MAVS through protein interaction or binding to RIG-I through a repressor domain directly, to inhibit the activation of RIG-I. LGP2 can increase the ability of MDA5 to form stable filaments on dsRNA to promote the MDA5-mediated pathway. LGP2 interacts with TRAF and disrupt its activity, which results in the disruption of IRFs and NF-κB activation. Activated RIG-I and MDA5 induce the recruitment and polymerization of the adapter MAVS on the mitochondrial membrane. Then MAVS activates TBK1 as well as the IKK complex, which activates IRF3 and IRF7, and NF-κB. And the gene expression of IFNs, pro-inflammatory cytokines and chemokines is induced to defend viral and modulate the immunity.

Following the recognition of dsRNAs via CTD of RLRs, the structural rearrangements allow the CARDs to induce the recruitment and polymerization of the adapter mitochondrial antiviral signaling (MAVS) on the mitochondrial membrane, which serves as a scaffold for the activation of TNF receptor-associated factor (TRAF) family (TRAF2,3,5,6). Besides, the TRAF propagates the signal sequentially from MAVS to TANK-binding kinase 1 (TBK1) and IκB kinase (IKK), and activates the transcription factors interferon regulatory factor 3 (IRF3) and nuclear factor-κB (NF-κB) to stimulate the transcription of type I IFNs and antimicrobial inflammatory cytokines, respectively (Fig. 1). Another RLRs member LGP2 was originally regarded as an inhibitor of RIG-I sensing IFN signaling via binding RNA ligands of RIG-I, interfering with IKK recruitment to MAVS through protein interaction or binding to RIG-I through a repressor domain directly. However, LGP2 null mice display reduced responses to several RNA viruses detected by MDA5. The high basal ATP hydrolysis activation of LGP2 enhances its RNA recognition capacity and diversity, which increases the ability of MDA5 to form stable filaments on dsRNA and synergizes with MDA5 to increase the antiviral response. LGP2 interacts with TRAF and disrupts its activity, which results in the disruption of IRF3 and NF-κB activation. Therefore, the function of LGP2 might be context-dependent.

RLRs expressed in non-immune cells including some cancer cells, and RLRs stimulation via their ligands mimic the viral infection could induce apoptosis through upregulation of the pro-apoptotic gene TRAIL and downregulation of the anti-apoptotic genes BCL2, BIRC3, and PRKCE via IRF3 and IRF7. Meanwhile, RLRs activation could stimulate innate and adaptive immune...
Toll-like receptors (TLRs) mediated signal transduction pathway. Toll-like receptors (TLRs) are comprised of at least 11 members. Among 11 members, TLR3, TLR7, TLR8, TLR9 were found to localize on endosome membrane and play an essential role in nucleic acid-sensing. TLR7 and TLR8, and unmethylated CpG motif of ssDNA can activate TLR9. TLRs are comprised of the N-terminal extracellular domain (ECD), transmembrane domain (TM), and C-terminal cytoplasmic Toll/IL-1 receptor domain (TIR). ECD domain is responsible for binding pathogen-associated molecular patterns (PAMPs), and the signaling cascades are conducted through the TIR domain, which recruits TRIF or Myd88 as adapters, to activate NFκB and IRFs. TLR3 can detect dsRNA, and TLR7 and TLR8, recognized ssRNA. And unmethylated CpG motif of ssDNA can activate TLR9. TLRs are comprised of the N-terminal extracellular domain (ECD), transmembrane domain (TM), and C-terminal cytoplasmic Toll/IL-1 receptor domain (TIR). ECD domain is responsible for binding pathogen-associated molecular patterns (PAMPs), and the signaling cascades are conducted through the TIR domain, which recruits TRIF or Myd88 as adapters, to activate NFκB and IRFs.

Toll-like receptors

Another type of PRRs is Toll-like receptors (TLRs), comprising at least 11 members, playing important roles in inducing antimicrobial innate and adaptive immune responses. Among these members, TLR3, TLR7, TLR8, TLR9 were found to play an essential role in nucleic acid-sensing (Fig. 2). Generally, TLRs are comprised of the N-terminal extracellular domain (ECD), transmembrane domain (TM), and C-terminal cytoplasmic Toll/IL-1 receptor domain (TIR). ECD domain is responsible for binding pathogen-associated molecular patterns (PAMPs), and the signaling cascades are conducted through the TIR domain, which recruits TRIF-domain-containing adapter protein including IFN-β (TRIF) or Myd88 as adapters, to activate NFκB and IRFs. For example, TLR3 is expressed on both cell and endosomal membranes in most innate immune cells. After recognizing virus-derived dsRNA and incomplete stem structures containing single-strand RNA ssRNA within endosomes, TLR3 oligomerizes and recruits the TICAM-1, and subsequently activates IRF3 and NFκB, to enhance the production of type I IFNs such as IFNβ and proinflammatory cytokines such as TNF-α and IL-6. Upon infection, TLR9 is critical to initiate innate immune responses via increasing proinflammatory cytokines and activating the cytotoxic NK cells and CD8+ T cells.

TLR9 is expressed dominantly in pDCs and B cells, and the unmethylated CpG motif of ssDNA is indispensable for TLR9 stimulation. By processing double strands DNA (dsDNA, such as chromosomal and mitochondrial DNA) into short ssDNA, DNases are essential to activate TLR9. Upon infection, TLR9 is critical to initiate innate immune responses via increasing proinflammatory cytokines and activating the cytotoxic NK cells and CD8+ T cells.

cGAS-STING pathway

Cyclic GMP-AMP synthase (cGAS) was first identified as a cytosolic double strands DNA (dsDNA) sensor in 2013. After binding to DNA directly, cGAS could covert GTP and ATP into cyclic GMP-AMP (cGAMP) to form the second messenger 2′,3′-cGAMP for the activation of stimulator of interferon genes (STING). Once bound by 2′,3′-cGAMP, STING translocates from ER to Golgi to form a complex with TBK1 or IKK. STING-activated TBK1 is able to phosphorylate IRF3, promoting IRF3 dimerization and translocation to the nucleus where it induces the transcription of many inflammation genes especially IFNβ. On the other hand, STING-activated IKK could phosphorylate IκBα, which leads to the translocation of NFκB to the nucleus, and then activates the transcription of proinflammatory cytokines (Fig. 3).
Although foreign or self DNA can activate cGAS in a length-dependent manner, healthy cells can digest the host dsDNA precisely via Dnase or compartmentalize the DNA in the nucleus or mitochondria to prevent the aberrant activation of cGAS-STING pathway. Respectively, mutation of Dnase or STING, self-DNA accumulation caused by DNA damage, chromosome instability, mitochondrial dysfunction, and so on, could activate the cGAS-STING pathway aberrantly, thereby leading to various inflammatory diseases, including tumorigenesis.

Inflammasomes

Inflammasomes are large multi-protein complexes to mediate the cytokines maturation and secretion, and pyroptosis. There are three components in a typical inflammasome: sensor, adapter, and effector. And the inflammasome sensors are usually divided into three classes: (1) Absent in melanoma 2 pyrin and hemopoietic ammasome (PYHIN) family, (2) nucleotide binding domain and leucine-rich repeats (NLR) containing protein family, (3) TRIM family member, Pyrin. Inflammasome sensors can detect the presence of pathogen-derived molecular, including nucleic acids, metabolites, and so on. Adapter proteins deliver the signal from the sensors to effectors through protein-protein interactions. And the effector drives the cleavage of pro-inflammatory cytokines (pro-IL-1β and pro-IL-18) and Gasdermin D, which leads to the secretion of mature interleukin-1β (IL-1β) and IL-18 and pyroptosis (Fig. 4). IL-18 has been shown to induce IFNγ production, increase NK cell activity and T cell proliferation. IL-1 can promote Th17 polarization to secrete IL-17 alongside with IFNγ. Moreover, IL-1 can promote T cell proliferation, and suppress regulatory T cells and IL-10 production by T cells. Paracrine of IL-1 can contribute to mature DCs, which promotes CD8+ T cell responses.

Among the three classes of sensors, PYHIN family members absent in melanoma 2 (AIM2) and interferon-inducible protein 16 (IFI16) were regarded as DNA sensors. AIM2 consists of an N-terminal pyrin domain (PYD) and a C-terminal HIN-200 domain. dsDNA binds to the HIN domain of AIM2 to free the PYD domain of AIM2. And the free PYD domain interacts with the PYD-CARD-containing inflammasome adapter protein apoptosis-associated speck-like protein containing a carboxy-terminal CARD (ASC) into helical filaments, which leads the activation of the effector caspase-1. IFI16 containing a PYD and two HIN domains, is the first PYD-containing protein sensing DNA to mediate IFNβ induction. IFI16 recognizes dsDNA from invaded DNA viruses, ssDNA from HIV infected CD4+ T cells, and the nuclear damaged DNA from etoposide-treated keratinocytes. Apart from triggering ASC-caspase 1 dependent inflammasome to produce IL-1β, activated IFI16 can recruit STING to activate IRF3 and NfkB to induce type I IFN. Another study found that STING can interact directly with IFI16 and facilitate IFI16 ubiquitination on the lysine3/4/6 and degradation via the ubiquitin-proteasome pathway by recruiting the ubiquitin E3 ligase TRIM21. In addition, during Mycobacterial infection, activated AIM2 mediated inflammasomes can interact with STING and block the activation of TBK1 and IRF3, thus inhibiting the induction of IFN-β.

The NLR containing protein 3 (NLRP3) has been well characterized to play important roles in viral infection and viral nucleic acid sensing. However, it is unclear whether NLRP3 directly senses viral DNA or RNA.

Other nucleic acid sensors

Z-DNA-binding protein 1 (ZBP1) could bind dsDNA directly, and activate the innate response via activating IRF3 and NfkB. In addition, it can sense RNA to trigger necroptosis via recruiting RIPK3 to phosphorylate and activate MLKL, which leads to virus-infected cell death. LRRFIP1 was reported to recognize both RNA and DNA from viruses or bacteria, which could lead to accumulation and subsequent translocation into the nucleus of β-catenin to enhance the transactivation of IRF3. DEAD-box helicase 41 (DDX41) could sense dsDNA or c-di-GMP to induce innate immunity through binding and activating STING directly to
activate the transcription factors IRF3 and NFκB.75 Protein kinase RNA-activated (PKR) can recognize long viral dsRNA during HCV infection, and then undergoes dimerization and autophosphorylation. Phosphorylated PKR can block translation initiation via phosphorylating eIF2 on Ser51 to induce cell death,76 and activate NFκB via phosphorylating IKKB to induce innate immune. 77 Another group of non-RLR RNA helicases could also sense RNA and mediate in inflammasome, or enhance RLR signaling to enhance IFN response and virus infection inhibition effect.78 One study reported that, upon binding to dsDNA, the NOD-like receptor family CARD domain containing 3 (NLRC3) could unleash STING from its sequestration, which induces STING mediated immunity activation.79

THE COMBINATION OF NUCLEI ACID-SENSING IMMUNITY WITH ICIS AS A PROMISING STRATEGY IN CANCER IMMUNOTHERAPY

Given the primary role of nuclei acid-sensing induced immune responses in activating T cell functions, there are various studies pointing out the advantages of activating the nuclei acid-sensing immunity to enhance the effect of ICIs in cancer immunotherapy (summarized in Table 1).

The usage of sensor agonists RIG-I like receptor ligands. RIG-I like receptor ligands have been proved promising for the treatment of malignancies such as breast cancer, melanoma, pancreatic cancer and acute myeloid leukemia (AML) in preclinical models.31,30–82 RIG-I activation via short 5’ppp-RNA induced tumor rejection, and immunological memory formation in acute myeloid leukemia (AML) model as a result of type I IFN induction to increase the level of CXCL10 to activate CD4+ and CD8+ T cells.83 Accordingly, 5’ppp-RNA treatment could sensitive ICIs treatment in vivo.82,84 In primary human melanoma tissues, high expression of RIG-I was associated with T cell receptor and antigen presentation pathway activation, the prolonged overall survival of patients, and durable clinical responses to anti-CTLA-4 checkpoint blockade.85 Thus, the high expression of RIG-I in cancer cells may indicate a better response to immune checkpoint blockade which still needs further research. MDAs activation via poly I:C in pancreatic cancer cells, induced apoptosis and the production of type I IFN and pro-inflammatory cytokines, which led to the activation of DCs. And the activated CD8α+ DCs engulfed apoptotic tumor material and cross presented tumor-associated antigen to naive CD8+ T cells, which induced cytotoxic T lymphocyte (CTL) mediated lysis.86 Accordingly, phaseI/II clinical study was performed to evaluate the safety, tolerability, and anti-tumor activity of intratumoral (IT)/ intrasional (IL) injections of the agonist of RIG-I, MK-4621 (RGT100), as monotherapy or in combination with pembrolizumab in participants with advanced solid tumors (NCT03065023 and NCT03739138, summarized in Table 2).

TLRs agonists. Given the critical roles of TLRs in triggering innate immunity, various agents have been found to modulate immunity to anti-tumors.87,88 An artificial ligand to TLR3, a synthetic DNA-dsRNA hybrid molecule (ARNAX) can activate antigen-presenting dendritic cells to induce cytotoxic T lymphocyte proliferation through TLR3-TICAM-1-IRF3-IFNβ pathway.89 On the other hand, it can establish a tumor suppression microenvironment through inducing the expression of DCs recruitment-related genes including CCL4, CCL5, and CCL27. In addition, treatment of ARNAX with tumor-associated antigen could induce mRNA expression of genes related to cytotoxicity (IFNy, Gzmb, and Prf1) and chemokines recruiting the CTLs (Cxcl9 and Cxcl10) in tumors, induce effector CTLs infiltration, and facilitate Th1-type anti-tumor immunity in mouse model. Nevertheless, the combination of the anti-PD-L1 antibody with TLR3 specific adjuvant (ARNAX + tumor Antigen) induced a more effective tumor regression response in a mouse model.90
| Agents | targets | Cancer types | Biological roles | Reference (PMID) |
|--------|---------|--------------|------------------|-----------------|
| 5′- Triphosphate RNA | RIG-I | Acute myeloid leukemia | • Induces type I IFNs expression<br>• Increases the infiltration of CD4+ and CD8+ T cells<br>• Establishes therapeutic sensitivity to immune checkpoint inhibitors | 31740809, 30379158, 30852164 |
| Poly (I:C) | MDA5 | Pancreatic cancer | • Induces the expression of type I IFNs and other proinflammatory cytokines in tumor tissue<br>• Acts DCs, induces Th1 polarization, upregulates the expression of Fas and MHC-I, induces Fas-mediated apoptosis and cytotoxic T lymphocyte-mediated lysis | 25012502 |
| ARNAX | TLR3 | Lymphoma | • Induces Type I IFNs production<br>• Promotes accumulation of CD8+ T cells and CD8α+ DCs into tumors<br>• Synergistically induces anti-tumor immunity with the PD-L1 antibody. | 28564605 |
| BO-112 | TLR3/MDA5 | Melanoma, Colon carcinoma | • Induces the production of type I IFNs, IFNγ<br>• Activates CD8+ T lymphocytes and tumor antigen-specific cytotoxic T lymphocytes<br>• Induces tumor regression | 31046839 |
| Resiquimod | TLR7/8 | Pancreatic cancer | • Induces CD8+ T cell proliferation and effector function<br>• Decreases Th2 polarization among CD4+ T cells<br>• Increases the response to anti-PD-1 antibody in combination with irradiation | 31615993 |
| Imiquimod | TLR7 | Breast cancer | • Activates NK cells, macrophages and B lymphocytes in combination with laser irradiation can.<br>• Induces CD8+, CD3+, CD4+ and PD-1+ T cells infiltration of distant tumors.<br>• Increases the response to anti-PD-1 antibody in combination with irradiation | 30339018 |
| 3M-025 | TLR7/8 | Melanoma | • Induces CD8+ T cell proliferation and effector function<br>• Decreases Th2 polarization among CD4+ T cells<br>• Increases the level of CCL2 chemokines and infiltration of M1 phenotype-shifted macrophages<br>• Induces the production of type I IFN, IFNγ<br>• Activates CD8+ T cells, B cells, and pDC to induce tumor suppression<br>• Potentiates checkpoint blockade therapy | 25252955 |
| 1V270 | TLR7 | Head and neck squamous cell carcinoma | • Increases the ratio of M1 to M2 tumor-associated macrophages<br>• Promotes the infiltration of tumor-specific IFNγ producing CD8+ T cells<br>• Enhances the efficacy of anti-PD-1 treatment | 28931759 |
| SD-101 | TLR9 | Colon carcinoma | • Stimulates the TLR9 of pDCs to release IFNs and mature<br>• Increases the infiltration and expansion of CD8+ T cells.<br>• Overcomes resistance to PD-1 blockade | 27799536 |
| CMP-001 | TLR9 | Colon carcinoma, Pancreatic cancer | • Increases the production of IFNγ, IL-6, and IL-12<br>• Induces the infiltration of CD8+ T and NK cells<br>• Elicits anti-tumor immune response and improves the survival<br>• Overcomes tumors resistant to PD-1 blockade<br>• Synergistically induces tumor regression in combination with PD-LA antibody and CTLA-4 antibody | 32409965, 31533840 |
| STINGVAX | STING | Melanoma | • Increases the tumor-infiltrating CD8+ IFNγ+ T cells induces the expression of PD-L1 in tumor<br>• Overcomes tumors-resistant to PD-1 blockade<br>• Synergistically induces tumor regression in combination with PD-LA antibody and CTLA-4 antibody | 25877890, 31533840 |
| ADU-S100 | STING | HPV+ oral cancer | • Synergistically induces tumor regression in combination with PD-LA antibody and CTLA-4 antibody | 25877890, 31533840 |
| 2′3′-c-di-AMP (PS) 2 (Rp, Rp) | STING | High-grade serous ovarian cancer | • Induces the production of IFNs<br>• Increases antigen presentation and MHC genes in tumors<br>• Increases the tumor infiltration of PD-1+ , CD69+ CD62L−, CD8+ T cells<br>• Synergistically induces tumor regression in combination with PD-LA antibody<br>• Increases T cell infiltration and reduces suppressive myeloid polarization<br>• Potentiates systemic checkpoint modulation | 30046165, 28674082 |
| Cyclic di-GMP | STING | Prostate cancer | • Induces the production of IFNs<br>• Increases antigen presentation and MHC genes in tumors<br>• Increases the tumor infiltration of PD-1+ , CD69+ CD62L−, CD8+ T cells<br>• Synergistically induces tumor regression in combination with PD-LA antibody<br>• Increases T cell infiltration and reduces suppressive myeloid polarization<br>• Potentiates systemic checkpoint modulation | 30046165, 28674082 |
| Target  | Agent                | Indication                  | Combination                          | Clinical trial ID | phase |
|---------|----------------------|-----------------------------|--------------------------------------|-------------------|-------|
| RIG-I   | MK-4621/JetPEI™      | Solid tumors                | Pembrolizumab                        | NCT03739138       | I     |
| TLR3    | Poly(I:C12U) (Rintatolimod; Ampligen) | Breast Cancer               | Pembrolizumab                        | NCT03599453,      | I     |
|         |                      | Ovarian Cancer              | Pembrolizumab                        | NCT03734692       | II    |
|         |                      | Colorectal Adenocarcinoma   | Pembrolizumab                        | NCT04119830       | II    |
|         | Poly-ICLC (Hiltonol) | Colon Cancer                | Pembrolizumab                        | NCT02834052       | II    |
|         |                      | Solid tumors                | Nivolumab Pembrolizumab;             | NCT04093323       | II    |
|         |                      | Ovarian Cancer              | Pembrolizumab                        | NCT04024878       | I     |
|         |                      | Solid tumors                | Nivolumab Pembrolizumab              | NCT03633110       | II    |
|         |                      | Melanoma                    | Pembrolizumab; Atezolizumab Durvalumab | NCT03929029       | I     |
|         |                      | Lung Cancer                 | Pembrolizumab                        | NCT03597282       | I     |
|         |                      | Prostate Cancer             | Pembrolizumab                        | NCT03835533       | I     |
|         |                      | Breast Cancer               | Pembrolizumab                        | NCT03362060       | I     |
|         |                      | Follicular Lymphoma         | Nivolumab                             | NCT03121677       | I     |
|         |                      | Kidney Cancer               | Ipilimumab                           | NCT02950766       | I     |
|         |                      | Hepatocellular Carcinoma    | Nivolumab Ipilimumab                 | NCT04248569       | I     |
|         |                      | Glioma                      | Nivolumab                             | NCT02960230       | I     |
|         |                      | Colorectal Cancer           | Nivolumab                             | NCT04117087       | I     |
|         |                      | Pancreatic Cancer           | Ipilimumab                            | NCT04117087       | I     |
|         |                      | Breast Cancer               | Pembrolizumab; Durvalumab            | NCT02826434       | I     |
|         |                      | Sarcoma                     | Nivolumab                             | NCT04420975       | NA    |
| TLR7    | Imiquimod (R-837)    | Melanoma                    | Pembrolizumab Toripalimab            | NCT03276832,      | I     |
|         |                      | Solid Tumors                | Anti-PD-1 antibody                    | NCT04072900       | I     |
|         |                      | Breast Cancer               | Pembrolizumab                         | NCT03982004       | I     |
| TLR7/8 and RIG-I | CVB102 | Solid Tumors | Anti-PD-1 antibody | NCT03291002 | I |
| TLR8    | Motolimod (VTX2337) | Head and Neck Squamous Cell Carcinoma | Nivolumab | NCT04272333 | I |
|         |                      | Ovarian Cancer              | Pembrolizumab; Durvalumab            | NCT03596526       | I     |
| TLR9    | Tilsotolimod (IMO-2125) | Solid Tumor | Nivolumab; Ipilimumab | NCT03865082 | II |
|         |                      | Advanced Cancer             | Nivolumab; Ipilimumab                 | NCT04270864       | I     |
|         |                      | Melanoma                    | Ipilimumab                            | NCT03445533       | III   |
|         | Leftotolimod (MGN1703) | Advanced Cancers | Ipilimumab | NCT02668770 | I |
| SD-101  | Pancreatic Adenocarcinoma | Nivolumab | NCT04050085 | I |
|         | Prostate Cancer      | Pembrolizumab               | NCT03007732                           | II               |
|         | Breast Cancer        | Pembrolizumab               | NCT01042379                           | NA               |
| CMP-001 | Melanoma             | Pembrolizumab               | NCT03084640                           | I               |
|         |                      | Nivolumab                   | NCT02680184                           | I               |
|         |                      | Melanoma                    | Nivolumab                             | NCT04401995       | II    |
|         |                      | Lymph Node Cancer           | Nivolumab                             | NCT03618641       | II    |
|         | Lymphoma             | Pembrolizumab               | NCT03983668                           | II               |
|         | Colorectal Cancer    | Nivolumab; Ipilimumab       | NCT03570699                           | I               |
|         | Advanced Cancer      | Avelumab                    | NCT02554812                           | II               |
| IMO-2125 (Tilsotolimod) | Melanoma | Ipilimumab | NCT03445533 | III |
|         | Solid Cancer         | Nivolumab                   | NCT03865082                           | II               |
| STING   | MIW815 (ADU-S100)    | Head and Neck Cancer        | Pembrolizumab                         | NCT03937141       | II    |
|         |                      | Solid Tumors                | Ipilimumab                            | NCT02675439       | I     |
And the evaluated proliferation of antigen-specific CTLs of human peripheral blood mononuclear cells (PBMCs) was observed induced via ARNAX treatment combined with TAA. However, ARNAX has not yet entered clinical development.

Poly-I:LC (Hiltonol) is a synthetic Poly-I: C that can induce tumor specific NK cells, CTLs, and NK-T cell-mediated immune responses via activating TLR3 and MDAs. In addition, poly-I:LC was shown to be an effective adjuvant to prime antigen specific CD8+ T cells and prolong survival in murine models of glioma and melanoma. And various clinical studies have revealed the contributions of Poly-I:LC alongside tumor-specific antigens to improve immune responses.

BO-112 is a nanoplexed form of Poly I:C, which may activate sensors such as TLR3 and MDAs. Intratumoral BO-112 treatment leads to remarkable tumor regression dependent on type I IFN and gamma-interferon in the mouse models. Furthermore, more abundant CD8+ T lymphocytes and tumor antigen specific cytotoxic T lymphocytes were found following intratumoral BO-112 treatment. And intratumoral BO-112 administration showed unilaterally to bilaterally efficacy in tumor bearing mice conjunction with systemic anti-PD-L1 monoclonal antibodies.

The agonist of TLR7, Imiquimod (also known as R-837) is an immune response modifier and has been approved by U.S. Food and Drug Administration (FDA) for treatment of superficial basal cell carcinoma, genital warts and actinic keratosis. In the breast cancer model, Imiquimod in combination with laser irradiation can activate NK cells, macrophages and B lymphocytes via TLR-7 induced cytokines (IFN-a, IL-6 and TNF-a) to further enhance the activation of immune response. And it can induce much more CD8+, CD4+, CD4 and PD-1+ T cells in distant tumors. Thus, Imiquimod in combination with irradiation can increase the response to anti-PD-1 antibody. Moreover, it was described that several cases of melanoma patients successfully treated with combination of ipilimumab and Imiquimod.

The TLR7/8 agonist Resiquimod (R848) was revealed to activate pDCs and cDCs in vivo, which enhanced T cells priming in regional lymph nodes. And combining PD-L1 antibody treatment with resiquimod is useful to reduce tumor growth in two PD-L1 blockade-resistant tumor models. However, several clinical studies revealed that resiquimod as adjuvants for a melanoma vaccine is not sufficient to induce consistent antigen-specific CD8+ T cell responses. 3M-025 is another TLR7/8 agonist, which could induce an increased level of CCL2 chemokines, infiltration of M1 phenotype-shifted macrophages, cytotoxic T cells in melanoma mouse model. Meanwhile, TLR7/8 agonist-loaded nanoparticles with tumor associated macrophage (TAM) avidity could reverse the polarization of TAM from the M2-like phenotype (anti-inflammatory) to M1-like phenotype (pro-inflammatory) and inhibit tumor growth in a CD8+ T cell-dependent manner in vivo. Accordingly, the combination of TLR7/8 with anti-PD-1 and anti-CTLA-4 resulted in a synergy of tumor regression.

Motolimod (VTX-2337) is a specific TLR8 agonist that activates NK cells and augments antibody-dependent cellular cytotoxicity (ADCC). In addition, motolimod can facilitate the activation of NK cells and dendritic cell cross-priming of tumor specific CD8+ T cells in head and neck cancer. IMO-2125, the agonist of TLR9, was revealed to lead to the production of Th1-type cytokines and chemokines. Treatment of IMO-2125 directly into one tumor leads to potent tumor regression of the injected and un.injected distant tumors via the CD8+ T cell directed Th1 response with a long-term tumor specific memory in the colon carcinoma mouse model. And phase I/II clinical trials have shown that the combination of IMO-2125 and Ipilimumab is well-tolerated and actively promotes anti-tumor immune responses in melanoma. The treatment induced responses even in distant tumors that did not receive IMO-2125 treatment.

Intratumoral treatment of TLR9 agonist, SD-101, which stimulates the TLR9 of pDCs, can induce pDCs to release IFNs and mature, thus could induce the infiltration and expansion of CD8+ T cells. And accordingly, SD-101 treatment could overcome resistance to PD-1 blockade in the colon carcinoma mouse model. CMP-001, another agonist of TLR9 can also facilitate the anti-tumor immune response including the increased expression of chemokines, pro-inflammatory cytokines, and the infiltration of CD8+ T and NK cells, which improves the survival in colon carcinoma and pancreatic cancer. Furthermore, it’s inspiring that the agonists of TLR9, CMP-001, and SD-101, could stimulate TLR9 and induce pDCs to secrete type I IFNs and inflammatory chemokines, and facilitate cytotoxic T cells infiltration to potentially overcome the resistance of PD-1 blockade in metastatic melanoma patients.

Based on these promise evidence in the preclinical studies, several clinical trials were conducted with TLR agonists in combination with ICIs to evaluate the potential clinical efficacy (summarized in Table 2).

**STING agonists.** Since STING is widely expressed in various types of cells in tumor tissues, synthetic STING agonists such as cyclic dinucleotide (CDNs) or cyclic di-GMP (CDG), could stimulate STING pathway in DCs, macrophages, B cells and other leukocytes to induce the production of Type I IFNs. The IFNs, in an autocrine or paracrine manner, could facilitate the antigen presentation to CD4+ and CD8+ T cells of DCs, and the priming of NK cells, which potentiates anti-tumor responses. Many efforts are focused on the development of modified CDNs or other small molecules. STING agonists have shown significant therapeutic benefit via increasing DCs mediated CD8+ T cells infiltration into the tumor microenvironment in melanoma, acute myeloid leukemia, breast and colorectal cancer mouse models. STING agonist formulated cancer vaccine (STINGVAX) treatment could increase the tumor infiltrating CD8+ IFNγ+ T cells with marked PD-L1 upregulation in the melanoma mouse model, which could sensitize the PD-1 blockade. STING agonists induced systemic pro-inflammatory cytokines, antigen processing and presentation in DCs as well as elevated PD-1−CD8+ T cell ratio in mice with high-grade serous ovarian carcinoma. The combination of the carboplatin with STING agonist and PD-1 blockade significantly prolonged the survival of these mice. Similarly, STING agonists such as ADU-S100 (also known as MIBW15 or ML-RF-52 CDA), 2′-c-di-AMP (RS) 2 (Rp.Rp), and cyclic di-GMP could enhance the therapeutic efficacy of anti-PD-1/PD-L1 immunotherapy in colon cancer, HPV+ oral cancer, pancreatic cancer, prostate cancer and so on.

The combination of STING agonists with ICIs is promising to enhance the effect of ICIs in antitumor therapy by activating innate and adaptive immunity. As a result, there are several clinical trials being performed (summarized in Table 2).

**Induction of cytoplasmic RNA**

In addition, there are other strategies to stimulate nucleic acid sensors such as induction of cytoplasmic RNA or DNA from the host to mimic the microbial infections. For example, the inhibition of histone H3K4 demethylase LSD1 in tumor cells increases the exogenous retroviral sequences (ERVs) transcripts, which allows the formation of dsRNA. And LSD1 could induce the protein stability of AGO2 through enhancing the methylation of AGO2. AGO2 is the key component of the RNA-induced silencing complex (RISC) complex, which mediates the RNA silence. Therefore, inhibition of LSD1 increases the accumulation of dsRNA, which is sensed by MDAs and TLR3, and then activates the expression of IFNs and MHC-I expression in tumor cells. In addition, a synergy in controlling tumor growth between LSD1 inhibition and PD-1 blockade was observed in the B16 tumor and triple-negative breast cancer (TNBC) tumor mouse models as a
result of the enhanced tumor immunogenicity, T cell infiltration, and anti-tumor T cell immunity.\textsuperscript{122,123} Furthermore, LSD1 is overexpressed in tumors compared with normal tissues in a broad of cancers, which indicates LSD1 is a promising target to enhance the effect of ICIs.\textsuperscript{122}

Besides, the treatment of DNA-demethylating agent 5-aza-CdR in tumor cells can induce the transcription of specific ERVs, and increase cytoplasmic dsRNAs. And the increase of dsRNAs is detected via MDAs, which further induces IFN response to anti-tumor.\textsuperscript{124,125} In addition, 5-aza-CdR treatment can potentiate the anti-tumor effect of anti-CTLA-4 antibody in the breast cancer mouse model, which may be associated with high viral defense.\textsuperscript{126}

Recent studies showed that gain-of-function mutations of MDAS (GOF MDAS) lead to aberrant activation of its signaling, resulting in a variety of immune disorders, such as Aicardi-Goutières syndrome (AGS) and systemic lupus erythematosus (SLE).\textsuperscript{127–129} Further study indicates that the Alu: Alu hybrids formed of inverted repeats (IRs) which are abundant in the cytosol, are the primary ligands for GOF MDAS, while wild type MDAS has limited ability to recognize Alu: Alu hybrids. Interestingly, under the deficiency of ADAR1 (an A to I RNA editor), the unmodified Alu: Alu hybrids could activate wild type MDAS significantly, which induces the production of Type I IFNs significantly. On the other hand, upon IFNs response, ADAR1 deletion could activate another dsRNA sensor, PKR to induce apoptosis in several cancer cell lines.\textsuperscript{131} Furthermore, loss of ADAR1 can overcome the resistance to PD-1 checkpoint blockade as a result of a significant increase in IFNs production and immune cells, including CD4\textsuperscript{+} T cells, CD8\textsuperscript{+} T cells, NK cells, and decreasing in M2 type myeloid cells in mouse model.\textsuperscript{132}

Cyclin-dependent kinases 4 and 6 (CDK4/6) inhibitor have shown significant activity on inhibiting the phosphorylation retinoblastoma (RB) tumor suppressor, and subsequently inducing G1 cell cycle arrest in tumor cells.\textsuperscript{133} Apart from inducing cell cycle arrest, CDK4/6 inhibitor could reduce the activity of DNA methyltransferase 1 (DNMT1) in breast cancer cells, which reduces DNA methylation at ERV sequences and increases the levels of dsRNA within tumor cells. High levels of dsRNA trigger RNA recognition receptors such as RIG-I, LGP2 and MDAS, which in turn stimulates the production of type I IFNs and hence enhances tumor antigen presentation. In addition, CDK4/6 inhibitors suppress the proliferation of Tregs and promote cytotoxic T cell-mediated clearance of tumor cells.\textsuperscript{134} In vitro and in vivo studies revealed that CDK4/6 inhibition resulted in increased anti-tumor activity and sensitivity to the PD-1 blockade.\textsuperscript{135}

Therefore, the above studies indicate that induction of cytoplasmic RNA to induce innate immune in tumors via deleting LSD1 or ADAR1, or treatment of DNA-demethylating agent or CDK4/6 inhibitors, showed a promising effect to combine with ICIs to anti-tumor. However, further studies probably will focus on clinical translation such as LSD1 and ADAR1 inhibitor invention.

Induction of cytoplasmic DNA
Since several pivotal research revealing surveillance of microcili by cGAS, much attention was paid to the synergy between DNA damage and ICIs.\textsuperscript{136,137} Accumulation of cytoplasmic DNA in microcili of tumor cells, which was induced by radiation or chemotherapy agents (such as cisplatin and etoposide), DNA damage repair blockage (such as PARP inhibition and BRCA1 deficient), and CHK1 inhibition to prevent cell cycle arrest during DNA damage repair, could activate cGAS-STING pathway to induce the innate immunity.\textsuperscript{138–141}

However, there are different mechanisms underlying. For instance, radiation therapy could sensitize the ICIs, which might be mediated via resident and infiltrating polyclonal T cells, diversity of T cell receptor(TCR) repertoire of intratumoral T cells after radiation.\textsuperscript{142,143} Ataxia Telangiectasia Mutated (ATM) is an important component in DNA damage response (DDR) and plays a critical role in responding to radiation treatment induced DNA double strand breaks. In pancreatic cancer, the inhibition of ATM alone, or in combination with radiation, could increase the phosphorylation of the tyrosine kinase Src and subsequent phosphorylation of TBK1, which will increase the transcription of type I IFNs and the activation of innate immunity. As a result, ATM inhibition sensitizes cancer cells to ICIs.\textsuperscript{144}

CHK1 inhibitors or PARP inhibitors induced STING-dependent CXCL10 transcription from small cell lung cancer cell lines in vitro. Since CXCL10 is a chemokine important for recruiting immune cells, its increased production would sensitize cancer cells to ICIs treatment. Indeed, in the small cell lung cancer mouse model, PARP or CHK1 inhibition significantly potentiated the anti-tumor effect of PD-L1 blockade via STING mediated IRF3 activation, thereby inducing type I IFNs production and innate immune activation.\textsuperscript{139}

BRCA1 and BRCA2 are key components in DNA damage repair through homologous recombination (HR).\textsuperscript{145} BRCA1 deficiency-induced DNA damage could increase the micronuclei release into the cytoplasm of breast cancer cells. The micronuclei are sensed by cGAS/STING and induce CXCL10 and CXCL5 production, which increase the CD4\textsuperscript{+} and CD8\textsuperscript{+} T cells infiltration and antitumor efficacy through activating cGAS/STING pathway in tumor cells thereby paracrine activation of dendritic cells.\textsuperscript{146,147} In addition, the combination of PARP1/2 inhibitor and anti-PD-1 antibody demonstrated synergistic antitumor activities in BRCA1-deficient TNBC mouse model.\textsuperscript{148} Besides, in BRCA1-deficient ovarian cancer cells, treatment of PARP inhibitor combined with another immune checkpoint inhibitor, a CTLA-4 antibody, could increase T cell recruitment and activation, cytokine production, and lasting systemic effector/memory T cell immunity, which eventually bring about the treatment synergy.\textsuperscript{149}

Furthermore, a study revealed that the defects in double strand break (DSB) repair protein such as Ku70/80 complex or BRCA2 lead to ATR/CHK1 activation and subsequent increasing STAT1/STAT3 phosphorylation and IRF1 expression, which induces PD-L1 transcription.\textsuperscript{150} Besides, ATM and CHK1 inhibition could increase the IFNs autocrine and paracrine, which increase the STAT1/STAT3 phosphorylation via IFN receptors. And the phosphorylation of STAT1/STAT3 increases IRF1 expression, which induces PD-L1 expression on tumor cells. And the upregulation of PD-L1 expression could provide a theoretical basis for combination therapy with ICIs in another way.\textsuperscript{144,150,151}

Oncolytic viruses (OVs)
During the past decades, oncolytic viruses (OVs) have been generated from both DNA viruses and RNA viruses.\textsuperscript{152,153} There are numerous advantages of OVs as cancer therapeutic agents. OVs directly and selectively kill tumor cells through immunogenic cell death. In addition, viral elements (such as DNA and RNA) can bind to nucleic-acid receptors (such as TLRs, cGAS-STING, MDAS, RIG-I, and so on), which triggers the release of type I IFNs and chemokines.\textsuperscript{146–150} Moreover, the death of tumor cells results in the release of soluble tumor-associated antigens, viral pathogen-associated molecular patterns (PAMPs), and cell derived damage-associated molecular patterns (DAMPs). PAMPs and DAMPs could recruit and activate APCs to engulf soluble tumor antigens and migrate to regional lymph nodes to prime adaptive T cell response against tumor. On the other hand, virus infection can induce the expression of MHC class I, and recruitment of tumor-specific CD8\textsuperscript{+} T cells.\textsuperscript{155} Furthermore, excessive interferon production may induce immune-suppressive environment through increasing the expression of checkpoint molecules, such as PD1, PD-L1, and CTLA-4.\textsuperscript{135,158,159}
Early clinical trials of OVs have shown its safety and promising responses in a variety of tumors.\textsuperscript{160} And accordingly, it’s promising to combine the OVs with ICIs to accelerate the anti-tumor immune response and remove the barriers of T cell-mediated tumor killing. Indeed, preclinical experiments revealed that OVs could increase the sensitivity of tumors to ICIs via activating T cell activity.\textsuperscript{161–164} In line with these preclinical studies, there are multiple clinical trials adopted to investigate the combination of oncolytic virotherapy with ICIs in cancer therapy (summarized in Table 3).\textsuperscript{164} For example, one phase Ib clinical trial showed that oncolytic virotherapy could improve the efficacy of anti-PD-1 therapy with a higher overall response rate and complete response in metastatic melanoma via enhancing the CD8\textsuperscript{T} infiltration, PD-L1 expression, as well as IFN-\gamma expression.\textsuperscript{165} And an ongoing Phase III clinical trial is currently underway to better evaluate the efficacy of this combination therapy in patients with stage IIIb-IV melanoma (NCT02263508).
Therefore, oncolytic virotherapy showed attractive interests in cancer therapy, especially the in combination of ICIs.

CONCLUSIONS
Nucleic acid-sensing pathway plays critical roles in activating T cells functions in pathogen infection as well as cancer. Generally, high expressions or gain-of-function mutations of nucleic acid sensors, treatments with extensive ligands or agonists of the receptors in tumors, or induction of nucleic acid can mimic the pathogen infections to activate nucleic acid-sensing signalings. And the stimulation of nucleic acid-sensing signalings induces the transcription of type I IFNs and other cytokines, which are important for remodeling tumor microenvironment. As a result, more immune cells will be recruited and more cancer cells are induced to apoptosis. More importantly, PD-L1 expression in cancer cells is increased, indicating that ICIs would be more effective. Thus, activating nucleic acid-sensing innate immunity seems a rational strategy in synergy with ICIs to anti-tumors (Fig. 5).

However, when considering the combination of sensor agonists, the expression and the relevance of sensors can be various in different cancers. For instance, the high expression of RIG-I in ovarian cancer is correlated with higher tumor grade and poor outcome, as well as the higher expression of PD-L1 and the regulatory T cell-specific transcription factor FoxP3. In contrast, the low expression of RIG-I in hepatocellular carcinoma patients is positively correlated to short survival. Thus, the expression and the relevance of sensors in different tumor types should be considered in the combination of these sensor agonists with ICIs.

Emergence evidence revealed that nucleic acid receptors sense cytoplasmic RNA or DNA produced by chemotherapy, radiation therapy or DNA damage. For instance, AIM2 could sense ionizing radiation-induced DNA damage in the nucleus, to trigger caspase-1 mediated cell death in intestinal epithelial cells and bone marrow cells. However, deficiency of AIM2 could increase the phosphorylation of AKT at Ser473 to increase the proliferation of mice colon cancer cells independent of AIM2 mediated inflammation. cGAS could recognize cytoplasmic DNA or micronuclei produced by chemotherapy, radiation therapy, or DNA damage to activate innate immune. Nevertheless, DNA damage could induce nuclear translocation of cGAS, which could sense DNA double stranded breaks, and recruits PARP1 to inhibit DNA homologous recombination (HR) and promotes tumorigenesis in certain types of cancer. TLR3 signaling may also participate in pro-inflammatory reactions contributing to tumorigenesis. Taken together, when considering the strategies of activating nucleic acid-mediated immunity to sensitive the ICIs, researchers should keep in mind that other signaling pathways that could lead to either pro-tumor or anti-tumor effects need to be carefully considered. Interestingly, inhibition of ATR destabilizes PD-L1, which could sensitize tumor cells to T cell-mediated killing. Therefore, the effect of the combination of ATR inhibition and ICIs in cancer immunotherapy needs further study.

Nevertheless, unleashing the nucleic-acid-sensing mediated innate immunity fuels the accelerators of T cells, and ICIs release the multiple brakes on T cells. Accordingly, it’s promising to combine harnessing the nucleic acid-mediated immune response with ICIs in cancer immunotherapy. However, further researches should pay more attention to the homeostasis of the tumor immune-microenvironment, and emergent clinical translational studies are still needed for this synergy strategy.

ACKNOWLEDGEMENTS
This work was supported by the Natural Science Foundation of Zhejiang province (Grant number LR19H160003), the Medical Science and Health Technology Project of Zhejiang province (Grant number 2020RC067), and the Natural Science Foundation of Zhejiang province (Grant number Q18H160015). And all figures were created with BioRender.com.

ADDITIONAL INFORMATION
Competing interests: The authors declare no competing interests.
REFERENCES

1. Coley, W. B. The treatment of inoperable sarcoma by bacterial toxins (the mixed toxins of the Streptococcus erysipelas and the Bacillus prodigiosus). Proc. R. Soc. Med. 3, 1–48 (1910).

2. Pardoll, D. M. The blockade of immune checkpoints in cancer immunotherapy. Nat. Rev. Cancer 12, 252–264 (2012).

3. Topalian, S. L. et al. Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab. J. Clin. Oncol. 32, 1020–1030 (2014).

4. Garon, E. B. et al. Pembrolizumab for the treatment of non-small-cell lung cancer. N. Engl. J. Med. 372, 2018–2028 (2015).

5. Inarrairaegui, M., Melero, I. & Sangro, B. Immunotherapy of hepatocellular carcinoma: facts and hopes. Clin. Cancer Res. 24, 1518–1524 (2018).

6. Parisien, J. P. et al. RNA sensor LGP2 inhibits TRAF ubiquitin ligase to negatively regulate innate antiviral defenses through a shared repressor (KEYNOTE-012): a multicentre, open-label, phase 1b trial. Lancet Oncol. 17, 717–726 (2016).

7. Motzer, R. J. et al. Nivolumab versus everolimus in advanced renal-cell carcinoma. N. Engl. J. Med. 373, 1803–1813 (2015).

8. Ott, P., Amdur, O. F., Kaufman, H. L., Wigginton, J. M. & Wolchok, J. D. Combination immunotherapy: a road map. J. Immunother. 35, 6 (2017).

9. Venkataraman, T. et al. Loss of DExD/H box RNA helicase LGP2 manifests diminished antiviral responses. Cell 171, 711–723 e714 (2017).

10. Liu, S. et al. MAVS recruits multiple ubiquitin E3 ligases to activate antiviral signaling cascades. Cancer Cell 31, 1191–1205 (2017).

11. Bruns, A. M. et al. ATP hydrolysis enhances RNA recognition and antiviral signal transduction by the innate immune sensor, laboratory of genetics and phy-}

12. Barry, K. C. et al. A natural killer–dendritic cell axis de-}

13. Venkataraman, T. et al. Loss of DExD/H box RNA helicase LGP2 manifests dis-}

14. McNab, F., Mayer-Barber, K., Sher, A., Wack, A. & O'Gara, M. Type I interferon-induced deficiency for viral dsRNA recognition. Nat. Immunol. 15, 87–93 (2014).

15. Zitvogel, L., Galluzzi, L., Kepp, O., Smyth, M. J. & Kroemer, G. Type I interferons in anticancer immunity. Nat. Rev. Immunol. 15, 405–414 (2015).

16. Kato, H., Takahashi, K. & Fujita, T. RIG-I-like receptors: cytosolic sensors for non-self RNA. ImmunoL Rev. 243, 91–98 (2011).

17. Reikine, S., Nguyen, J. B. & Modis, Y. Pattern recognition and signaling mechanisms of RIG-I and MDA5. Front. Immunol. 5, 342 (2014).

18. Barry, K. C. et al. A natural killer–dendritic cell axis defines checkpoint therapy-responsive tumor microenvironments. Nat. Med. 24, 1178–1191 (2018).

19. Takeuchi, O. & Akira, S. Pattern recognition receptors and inflammation. Cell 140, 805–820 (2010).

20. Mcnab, F., Mayer-Barber, K., Sher, A., Wack, A. & O'Gara, M. Type I interferons in infectious disease. Nat. Rev. Immunol. 15, 87–93 (2015).

21. Spranger, S., Dai, D., Horton, B. & Gajewski, T. F. Tumor-residing Baf3 dendritic cells are required for effector T cell trafficking and adoptive T cell therapy. Cancer Cell 31, 711–723 e714 (2017).

22. Hornung, V. et al. Type I interferon pathway-mediated interferon-β induction. Nat. Immunol. 16, 161–167 (2015).

23. Reikine, S., Nguyen, J. B. & Modis, Y. Pattern recognition and signaling mechanisms of RIG-I and MDA5. Front. Immunol. 5, 342 (2014).

24. Yoneyama, M. et al. The RNA helicase RIG-I has an essential function in double-stranded RNA-induced innate antiviral responses. Nat. Immunol. 5, 730–737 (2004).

25. Hornung, V. et al. S ‘ -triphosphate RNA is the ligand for RIG-I. Science 314, 994–997 (2006).

26. Pesley, A. et al. Cooperative assembly and dynamic disassembly of MDAS filaments for viral dsRNA recognition. Proc. Natl Acad. Sci. USA 108, 21010–21015 (2011).

27. Jo, M. H. et al. Kinetic mechanism for viral dsRNA length discrimination by MDAS filaments. Biophys. J. 104, 420a–420a (2013).

28. Liu, S. et al. MAVS recruits multiple ubiquitin E3 ligases to activate antiviral signaling cascades. Elife 2, e00785 (2013).

29. Venkataraman, T. et al. Loss of DExD/H box RNA helicase LGP2 manifests defective antiviral responses. J. Immunol. 179, 6444–6455 (2007).

30. Yoneyama, M. et al. Shared and unique functions of the DExD/H-box helicases RIG-I, MDA5, and LGP2 in antiviral innate immunity. J. Immunol. 175, 2851–2858 (2005).

31. Saito, T. et al. Regulation of innate antiviral defenses through a shared repressor domain in RIG-I and LGP2. Proc. Natl Acad. Sci. USA 104, 582–587 (2007).

32. Bruns, A. M. et al. ATP hydrolysis enhances RNA recognition and antiviral signal transduction by the innate immune sensor, laboratory of genetics and phy-}

33. Parisien, J. P. et al. RNA sensor LGP2 inhibits TRAF ubiquitin ligase to negatively regulate innate immune signaling. EMBO Rep. 19, https://doi.org/10.15252/embr.201745176 (2018).

34. Wu, Y. B., Wu, X. Q., Wu, L. H., Wang, X. C. & Liu, Z. P. The anticancer functions of RIG-I-like receptors, RIG-I and MDA5, and their applications in cancer therapy. Transl. Res. 190, 51–60 (2017).

35. Kumar, S. et al. IPS-1 differentially induces TRAIL, BCL2, BIRC3 and PRKCCE in type I interferon-dependent and -independent antiviral activity. Cell Death Dis. 6, e1758 (2015).

36. Daweert, D. et al. RIG-I-like helicases induce immunogenic cell death of pancreatic cancer cells and sensitize tumors toward killing by CD8+ T cells. Cell Death Diff. 21, 1984–1984 (2014).

37. Ellermeier, J. et al. Therapeutic efficacy of bifunctional siRNA combining TGF-

beta1 silencing with RIG-I activation in pancreatic cancer. Cancer Res. 73, 1709–1720 (2013).

38. Chen et al. Targeting nuclear acid-mediated immunity in cancer immune checkpoint... Chen et al.
Targeting nuclear acid-mediated immunity in cancer immune checkpoint...